GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Total Tax Payable

Clarity Pharmaceuticals (ASX:CU6) Total Tax Payable : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Total Tax Payable?

Clarity Pharmaceuticals's Total Tax Payable for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Clarity Pharmaceuticals Total Tax Payable Historical Data

The historical data trend for Clarity Pharmaceuticals's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Total Tax Payable Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Total Tax Payable
- -

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Total Tax Payable Get a 7-Day Free Trial - - - - -

Clarity Pharmaceuticals Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Clarity Pharmaceuticals Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (ASX:CU6) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines